CCL2 and neuroblastoma: CCR2b, the cognate receptor for CCL2, has demonstrated a remarkable propensity to navigate towards CCL2-enriched microenvironments, thereby mobilizing CAR-Ts permeating into high-CCL2-expressing malignancies such as neuroblastoma and melanoma 140.